Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

BRUKER

BRUKER offers high-performance scientific instruments and high-value analytical and diagnostic solutions that enable ... read more Featured Products: More products

Download Mobile App




New Blood Test Can Predict Future Breast Cancer

By LabMedica International staff writers
Posted on 29 Apr 2015
The analysis of a blood sample could predict if a woman will get breast cancer within two to five years which could create a paradigm shift in early diagnosis of this malignant neoplasm as well as other diseases.

The method, called a metabolic blood profile is still in the early stages but over time the experts expect it could be used to predict breast cancer and more generally to predict chronic disease and the new method will lead to better prevention and early treatment of the disease. More...


Scientists at the University of Copenhagen (Frederiksberg, Denmark) used 20-year-old blood samples and other available data from 400 women who were healthy when they were first examined but who were diagnosed with breast cancer two to seven years after providing the first sample, and from 400 women who did not develop breast cancer. The team analyzed all compounds contained in the blood sample, instead of as is often done in health and medical science, examining what a single biomarker means in relation to a specific disease.

The plasma samples were analyzed by proton Nuclear Magnetic Resonance (1H NMR). NMR analysis was performed with a Bruker Avance III 600 spectrometer (Bruker Biospin Gmbh; Rheinstetten, Germany). The NMR spectra were subjectively evaluated by spectroscopists and data analysts in order to exclude as many noise regions from the data as possible and to include all peaks in the most parsimonious manner. The spectroscopists and data analysts were blinded to the case/control status.

While a mammography can detect newly developed breast cancer with a sensitivity of 75% the new metabolic blood profile is able to predict the likelihood of a woman developing breast cancer within the next two to five years with a sensitivity of 80%. The method was also used to test a different dataset of women examined in 1997. Predictions based on the new set of data matched the first dataset, which indicated the validity of the model.

Lars Ove Dragsted, PhD, a professor and senior author of the study said, “The potential is that we can detect a disease like breast cancer much earlier than today. This is important as it is easier to treat if you discover it early. In the long term, it will probably also be possible to use similar models to predict other diseases.” The study was published on March 10, 2015, in the journal Metabolomics.

Related Links:

University of Copenhagen 
Bruker Biospin Gmbh



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.